Einzeltreffer — DigiBib

B-cell subsets in peripheral blood (PB) and tumor microenvironment (TME) were evaluated to determine myasthenia gravis (MG) severity in patients with thymoma-associated MG (TMG) and the distribution of B cells in type B TMG. The distribution of mature B cells, including Bm1-Bm5, CD19 + and CD20 + B cells and non-switched (NSMBCs) and switched (SMBCs) memory B cells, were determined in 79 patients with thymoma or TMG. Quantitative relationships between the T and TMG groups and the TMG-low and TMG-high subgroups were determined. NSMBCs and SMBCs were compared in TME and PB. Type B thymoma was more likely to develop into MG, with types B2 and B3 being especially associated with MG worsening. The percentage of CD19 + B cells in PB gradually increased, whereas the percentage of CD20 + B cells and the CD19/CD20 ratio were not altered. The (Bm2 + Bm2')/(eBm5 + Bm5) index was significantly higher in the TMG-high than in thymoma group. The difference between SMBC/CD19 + and NSMBC/CD19 + B cell ratios was significantly lower in the thymoma than TMG group. NSMBCs assembled around tertiary lymphoid tissue in thymomas of patients with TMG. Few NSMBCs were observed in patients with thymoma alone, with these cells being diffusely distributed. MG severity in patients with TMG can be determined by measuring CD19 + B cells and Bm1-Bm5 in PB. The CD19/CD20 ratio is a marker of disease severity in TMG patients. Differences between NSMBCs and SMBCs in PB and TME of thymomas can synergistically determine MG severity in patients with TMG.

Titel:	Distribution of multi-level B cell subsets in thymoma and thymoma-associated myasthenia gravis.
Autor/in / Beteiligte Person:	Zhang, P ; Liu, Y ; Chen, S ; Zhang, X ; Wang, Y ; Zhang, H ; Li, J ; Yang, Z ; Xiong, K ; Duan, S ; Zhang, Z ; Wang, P
Link:	Zum Volltext
Zeitschrift:	Scientific reports, Jg. 14 (2024-02-01), Heft 1, S. 2674
Veröffentlichung:	London : Nature Publishing Group, copyright 2011-, 2024
Medientyp:	academicJournal
ISSN:	2045-2322 (electronic)
DOI:	10.1038/s41598-024-53250-6
Schlagwort:	Humans B-Lymphocytes pathology Tumor Microenvironment Thymoma complications Thymoma pathology B-Lymphocyte Subsets pathology Thymus Neoplasms complications Thymus Neoplasms pathology Myasthenia Gravis complications
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [Sci Rep] 2024 Feb 01; Vol. 14 (1), pp. 2674. <i>Date of Electronic Publication: </i>2024 Feb 01. MeSH Terms: Thymoma* / complications ; Thymoma* / pathology ; B-Lymphocyte Subsets* / pathology ; Thymus Neoplasms* / complications ; Thymus Neoplasms* / pathology ; Myasthenia Gravis* / complications ; Humans ; B-Lymphocytes / pathology ; Tumor Microenvironment References: Front Immunol. 2021 Nov 01;12:766698. (PMID: 34790201) ; Nat Immunol. 2019 Jan;20(1):97-108. (PMID: 30510223) ; Nature. 2020 Jan;577(7791):549-555. (PMID: 31942075) ; Cell Mol Immunol. 2017 Aug;14(8):662-674. (PMID: 28626234) ; Nat Rev Immunol. 2020 Apr;20(4):229-238. (PMID: 31836872) ; Cancer Res. 2016 Oct 1;76(19):5597-5601. (PMID: 27634765) ; Blood. 2006 Jul 15;108(2):432-40. (PMID: 16543475) ; Ann Rheum Dis. 2009 Sep;68(9):1447-52. (PMID: 18782791) ; Clin Rheumatol. 2020 May;39(5):1415-1421. (PMID: 32088800) ; Cancer Res. 2012 Aug 15;72(16):3997-4007. (PMID: 22850419) ; J Immunol. 2001 Aug 15;167(4):1935-44. (PMID: 11489973) ; Immunobiology. 2013 Mar;218(3):373-81. (PMID: 22704519) ; Ann N Y Acad Sci. 2018 Jan;1412(1):137-145. (PMID: 29125185) ; J Exp Med. 1994 Jul 1;180(1):329-39. (PMID: 8006591) ; J Immunol Res. 2020 Nov 28;2020:8209737. (PMID: 33313327) ; N Engl J Med. 2016 Aug 11;375(6):511-22. (PMID: 27509100) ; Ther Adv Neurol Disord. 2018 Mar 21;11:1756286418761697. (PMID: 29593838) ; J Autoimmun. 2020 Jan;106:102337. (PMID: 31594658) ; Semin Nephrol. 2020 Mar;40(2):206-215. (PMID: 32303283) ; Nat Rev Cancer. 2019 Jun;19(6):307-325. (PMID: 31092904) ; Immunol Rev. 2018 May;283(1):138-149. (PMID: 29664566) ; Annu Rev Immunol. 2017 Apr 26;35:255-284. (PMID: 28142324) ; Cancer Sci. 2020 Jun;111(6):1921-1932. (PMID: 32277550) ; Nat Rev Drug Discov. 2021 Mar;20(3):179-199. (PMID: 33324003) ; Nat Commun. 2021 Jun 7;12(1):3349. (PMID: 34099645) ; Clin Rheumatol. 2021 Jan;40(1):151-165. (PMID: 32542581) ; J Immunol. 2001 Oct 1;167(7):3610-8. (PMID: 11564773) ; Clin Rev Allergy Immunol. 2017 Feb;52(1):108-124. (PMID: 27273086) ; Ann Oncol. 2015 Sep;26 Suppl 5:v40-55. (PMID: 26314779) ; J Immunol. 2015 Oct 15;195(8):3716-24. (PMID: 26355154) ; Immunity. 2021 Dec 14;54(12):2812-2824.e4. (PMID: 34861182) ; Nat Rev Dis Primers. 2019 May 2;5(1):30. (PMID: 31048702) ; Oncoimmunology. 2017 Mar 3;6(4):e1294296. (PMID: 28507802) Grant Information: 19JCZDJC64400 the Beijing-Tianjin-Hebei Basic Research Co-operation Project; TJNMDF2020YB-01 the Tianjin Northern Medicine Development Foundation; 19JCZDJC35500 the Tianjin Natural Science Foundation of Key Program; 19JCQNJC12000 the Tianjin Natural Science Foundation of Youth Program, Entry Date(s): Date Created: 20240201 Date Completed: 20240205 Latest Revision: 20240205 Update Code: 20240205 PubMed Central ID: PMC10834956

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Distribution of multi-level B cell subsets in thymoma and thymoma-associated myasthenia gravis.